Two Cambridge institutes have today been confirmed as major research centres by biomedical research charity Wellcome, receiving continued support for a further five years. The centres will be co-funded by Cancer Research UK (CRUK) and the Medical Research Council (MRC) respectively.
Cambridge spin-out Carrick Therapeutics raises $95 million in funding, representing the largest-ever early stage investment in a UK university spin-out company.
Scientists have identified for the first time the ‘cell of origin’ – in other words, the first cell from which the cancer grows – in basal cell carcinoma, the most common form of skin cancer, and followed the chain of events that lead to the growth of these invasive tumours.
Winners announced in the inaugural Vice-Chancellor’s Impact Awards and Public Engagement with Research Awards21 Jun 2016
Researchers from across the University have been recognised for the impact of their work on society, and engagement with research in the inaugural Vice-Chancellor’s Impact Awards and Public Engagement with Research Awards.
Prof. Steve Jackson of the Wellcome Trust/ Cancer Research UK Gurdon Institute, University of Cambridge, has won the 2016 Dr A. H. Heineken Prize for Medicine, for "his fundamental research into DNA repair in human cells and for the successful application of knowledge of that process in the development of new cancer drugs".
Tumours kill off surrounding cells to make room to grow, according to new research from the University of Cambridge. Although the study was carried out using fruit flies, its findings suggest that drugs to prevent, rather than encourage, cell death might be effective at fighting cancer – contrary to how many of the current chemotherapy drugs work.
The world of epigenetics – where molecular ‘switches’ attached to DNA turn genes on and off – has just got bigger with the discovery by a team of scientists from the University of Cambridge of a new type of epigenetic modification.